Developing a Randomised Efficacy PREcision medicine Platform trial design for Cavernomas: the CARE PREP study
Authors:
- Rustam Al-Shahi SalmanRSRustam Al-Shahi Salman
- Kasia AdamczukKAKasia Adamczuk
- Richard A ParkerRPRichard A Parker
- Christopher J WeirCWChristopher J Weir
- Roberto LatiniRLRoberto Latini
- Helen KimHKHelen Kim
- David WhiteDWDavid White
- Helen EvansHEHelen Evans
- Jana BergholtzJBJana Bergholtz
- Cornelia LeeCLCornelia Lee
- Carlos CasausCCCarlos Casaus
Open Access
- 1 March 2025
- journal article
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-21
Abstract
Background: Symptomatic cerebral cavernous malformations are a rare sporadic or familial disease, which may cause haemorrhagic strokes or epileptic seizures. In 2015, a James Lind Alliance Priority Setting Partnership ranked targeted drug therapies as fourth of the top 10 research priorities for cerebral cavernous malformations. There are no disease-modifying drugs for cerebral cavernous malformations, but there are several promising candidates with proof of concept in human and animal studies. There are no platform trials for cerebral cavernous malformations. Objectives: (1) Consolidate and initiate international collaborations between cerebral cavernous malformations researchers, cerebral cavernous malformations patient and public involvement groups, cerebral cavernous malformations research networks, and commercial partners; (2) Finalise a protocol for an efficient, international platform trial of multiple drugs using precision medicine (sporadic vs. familial cerebral cavernous malformations) that is both feasible and acceptable to patients and regulators; (3) Estimate the research, support and treatment costs of the platform trial and apply to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation Programme. Methods: A National Institute for Health and Care Research Efficacy and Mechanism Evaluation Application Acceleration Award funded this project from September 2022 to August 2023. A trial manager supported the Chief Investigator in growing and leading a multidisciplinary international collaboration, including a patient and public involvement advisory group, in a series of meetings to optimise study design, equality, diversity and inclusion. Edinburgh Innovations established connections with commercial partners with candidate drugs. We assessed feasibility by scoping potential funding agencies, and clinical networks that might support recruitment internationally. We agreed upon a final design and sample size through a process of consensus, enlightened by scenarios simulated by statisticians varying key parameters, which informed a comprehensive estimate of the budget for a stage 1 submission to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation programme. Setting: International collaboration. Participants: Clinicians, researchers, patient and public involvement groups, cerebral cavernous malformations research networks, and commercial partners. Results: There was one face-to-face meeting, nine virtual meetings of the co-applicants, and five meetings of the patient and public involvement advisory group. We identified 14 countries with clinical leadership, a cerebral cavernous malformation research network, and a funding agency that could support an international trial. We contacted three potential commercial partners and obtained one letter of collaboration. We sent monthly newsletters to collaborators. Our meetings and simulations concluded that a three-arm, two-stage multiarm multistage adaptive treatment selection randomised trial design was suitable for evaluating aspirin and propranolol as the first two interventions compared with standard care in a platform trial. We submitted a stage 1 proposal for this Cavernous malformations A Randomised Efficacy MAster Protocol study to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation call 23/15 in May 2023, and a resubmission was encouraged. Limitations: The National Institute for Health and Care Research Efficacy and Mechanism Evaluation funding committee would have required further justification for the choice of the intermediate phenotype used for treatment selection, biomarker validation work, and details about the pipeline of interventions. Future work: We have addressed these limitations and re-applied to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation programme. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme as award number NIHR153811.Keywords
Funding Information
- Public Health Research Programme (NIHR153811)
This publication has 72 references indexed in Scilit:
- Addressing barriers and identifying facilitators to support informed consent and recruitment in the Cavernous malformations A Randomised Effectiveness (CARE) pilot phase trial: insights from the integrated QuinteT recruitment intervention (QRI)eClinicalMedicine, 2024
- Perfusion and PermeabilityMRIPredicts Future Cavernous Angioma Hemorrhage and GrowthJournal of Magnetic Resonance Imaging, 2021
- Surgery for cerebral cavernous malformations: a systematic review and meta-analysisNeurosurgical Review, 2021
- When Can Intermediate Outcomes Be Used as Surrogate Outcomes?JAMA, 2020
- Effect of Simvastatin on Permeability in Cerebral Cavernous Malformation Type 1 Patients: Results from a Pilot Small Randomized Controlled Clinical TrialTranslational Stroke Research, 2019
- Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult DiseaseJAMA Neurology, 2019
- Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhageJournal of Magnetic Resonance Imaging, 2017
- Population-Based Prevalence of Cerebral Cavernous Malformations in Older AdultsJAMA Neurology, 2017
- Successful treatment of multifocal intracerebral and spinal hemangiomas with propranololJournal of the American Academy of Dermatology, 2014
- Genotype–phenotype correlations in cerebral cavernous malformations patientsAnnals of Neurology, 2006